Blood groups and susceptibility to virus infection: New developments

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 558-564

  Branch, Donald R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gb3; globotriaosylceramide; HIV; natural resistance; P1PK and GLOB blood group systems; Pk blood group antigen

Indexed keywords

1 DEOXYGALACTONOJIRIMYCIN; ALPHA 1,4 GALACTOSYLTRANSFERASE; BETA 1,3 N ACETYLGALACTOSAMINYLTRANSFERASE 1; BLOOD GROUP ANTIGEN; BLOOD GROUP P K ANTIGEN; GALACTOSYLTRANSFERASE; GLOBOTRIAOSYLCERAMIDE; GLYCOPROTEIN GP 120; GLYCOSPHINGOLIPID; IMINOSUGAR; N ACETYLGALACTOSAMINYLTRANSFERASE; UNCLASSIFIED DRUG;

A4GALT GENE; B3GALNT1 GENE; BLOOD GROUP; BLOOD GROUP P SYSTEM; CD4+ T LYMPHOCYTE; CELL MEMBRANE; DISEASE PREDISPOSITION; FABRY DISEASE; GENE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS INHIBITION;

BLOOD GROUP ANTIGENS; GLYCOSPHINGOLIPIDS; HIV INFECTIONS; HIV-1; HUMANS;

EID: 78049314630     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833ece31     Document Type: Review

References (65)

1. Anstee DJ.The relationship between blood groups and disease. Blood 2010; 115:4635-4643.
2. Moulds JM, Nowicki S, Moulds JJ, Nowicki BJ. Human blood groups: incidental receptors for viruses and bacteria. Transfusion 1996; 36:362-374.
3. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262:114-117.
4. Kaufmann B, Baxa U, Chipman PR, et al. Parvovirus B19 does not bind to membrane-associated globoside in vitro. Virology 2005; 332:189-198.
5. Musken A, Souady J, Dreisewerd K, et al. Application of thin-layer chromato-graphy/infrared matrix-assisted laser desorption/ionization orthogonal time-of-flight mass spectrometry to structural analysis of bacteria-binding glyco-sphingolipids selected by affinity detection. Rapid Commun Mass Spectrom 2010; 24:1032-1038.
6. Spitalnik PF, Spitalnik SL. The P blood group system: biochemical, serological, and clinical aspects. Transfus Med Rev 1995; 9:110-122.
7. Sheffield WP, Tinmouth A, Branch DR. Blood group biochemistry: a Canadian blood services research and development symposium. Transfus Med Rev 2005; 19:295-307.
8. Lingwood CA, Binnington B, Manis A, et al. Globotriaosyl ceramide receptor function: where membrane structure and pathology intersect. FEBS Lett 2010; 584:1879-1886.
9. Schwartz-Albiez R, Dorken B, Moller P, et al. Neutral glycosphingolipidsof the globo-series characterize activation stages corresponding to germinal center B cells. Int Immunol 1990; 2:929-936.
10. Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol 1996; 4:147-153.
11. Lingwood CA. Glycolipid receptors for verotoxin and Helicobacter pylori: role in pathology. Biochim Biophys Acta 1999; 1455:375-386.
12. Okuda T, Tokuda N, Numata S, et al. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphin-golipids and loss of sensitivity to verotoxins. J Biol Chem 2006; 281:10230-10235.
13. Johannes L, Romer W. Shiga toxins: from cell biology to biomedical applications. Nat Rev Microbiol 2010; 8:105-116.
14. Lund N, Olsson ML, Ramkumar S, et al. The human P(k) histo-blood group antigen provides protection against HIV-1 infection. Blood 2009; 113:4980-4991.
15. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425-1431.
16. Marcus DM. The Ii and P blood group systems. Immunol Ser 1989; 43:701-712.
17. Hakomori S. Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochim Bophys Acta 2008; 1780:325-346.
18. Lannert H, Gorgas K, Meissner I, et al. Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis. Lactosylceramide and subsequent glycosphingolipids are formed in the lumen of the late Golgi. J Biol Chem 1998; 273:2939-2946.
19. Kojima Y, Fukumoto S, Furukawa K, et al. Molecular cloning of globotriao-sylceramide/CD77 synthase, a glycosytransferase that initiates the synthesis of globo series glycosphingolipids. J Biol Chem 2000; 275:15152-15156.
20. Keusch JJ, Manzella SM, Nyame KA, et al. Cloning of Gb3 synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of alpha 1,4-glycosyltransferases conserved in plants, insects, and mammals. J Biol Chem 2000; 275:25315-25321.
21. Steffensen R, Carlier K, Wiels J, et al. Cloning and expression of the histo-blood group Pk UDP-galactose: Ga1beta-4G1cbeta1-cer alpha1,4-galacto- syltransferase. Molecular genetic basis of the p phenotype. J Biol Chem 2000; 275:16723-16729.
22. Okajima T, Nakamura Y, Uchikawa M, et al. Expression cloning of human globoside synthase cDNAs. Identification of beta 3Gal-T3 as UDP-N-acet- ylgalactosamine: globotriaosylceramide beta 1,3-N-acetylgalactosaminyl- transferase. J Biol Chem 2000; 275:40498-40503.
23. Daniels G. Human blood groups. Malden, Massachusetts, USA: Blackwell Science; 2002.
24. Hellberg A, Chester MA, Olsson ML. Two previously proposed P1/P2-differentiating and nine novel polymorphisms at the A4GALT (Pk) locus do not correlate with the presence of the P1 blood group antigen. BMC Genet 2005; 6:49.
25. Hellberg A, Poole J, Olsson ML. Molecular basis of the globoside-deficient P(k) blood group phenotype. Identification of four inactivating mutations in the UDP-N-acetylgalactosamine:globotriaosylceramide 3-beta-N-acetylgalacto-saminyltransferase gene. J Biol Chem 2002; 277:29455-29459.
26. Hellberg A, Ringressi A, Yahalom V, et al. Genetic heterogeneity at the glycosyltransferase loci underlying the GLOB blood group system and collection. Br J Haematol 2004; 125:528-536.
27. Furukawa K, Iwamura K, Uchikawa M, et al. Molecular basis for the p phenotype. Identification of distinct and multiple mutations in the alpha 1,4-galactosyltransferase gene in Swedish and Japanese individuals. J Biol Chem 2000; 275:37752-37756.
28. Hellberg A, Steffensen R, Yahalom V, et al. Additional molecular bases of the clinically important p blood group phenotype. Transfusion 2003; 43:899-907.
29. Clarke JT. Narrative review: Fabry disease. Ann Intern Med 2007; 146:425-433.
30. Das AM, Naim HY. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. Adv Clin Chem 2009; 49:57-71.
31. Leffler H, Svanborg-Eden C. Glycolipid receptors for uropathogenic Escherichia coli on human erythrocytes and uroepithelial cells. Infect Immun 1981; 34:920-929.
32. Korhonen TK, Vaisanen V, Saxen H, et al. P-antigen-recognizing fimbriae from human uropathogenic Escherichia coli strains. Infect Immun 1982; 37:286-291.
33. Haataja S, Tikkanen K, Nilsson U, et al. Oligosaccharide-receptor interaction of the Gal alpha 1-4Gal binding adhesin of Streptococcus suis. Combining site architecture and characterization of two variant adhesion specificities. J Biol Chem 1994; 269:27466-27472.
34. Pellizzari A, Pang H, Lingwood CA. Binding of verocytotoxin 1 to is receptor is influenced by differences in receptor fatty acid content. Biochemistry 1992; 31:1363-1370.
35. Bitzan M, Richardson S, Huang C, et al. Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun 1994; 62:3337-3347.
36. k antigen) and a novel platelet glycosphingolipid. Infect Immun 1998; 66:4355-4366.
37. Karmali MA. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 1989; 2:15-38.
38. Brown KE, HIbbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192-1196.
39. Bhat S, Spitalnik SL, Gonzalez-Scarano F, Silbergerg DH. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci \USA 1991; 88:7131-7134.
40. Hammache D, Pieroni G, Yahi N, et al. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monlayers of galactosylceramide and ganglioside GM3. J Biol Chem 1998; 273:7967-7971.
41. Long D, Berson JF, Cook DG, Doms RW. Characterization of human immunodeficiency virus type 1 gp120 binding to lipsomes containing galactosyl-ceramide. J Virol 1994; 68:5890-5898.
42. Puri A, Hug P, Jernigan K, et al. The neutral glycosphingolipid globotriao-sylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc Natl Acad Sci \USA 1998; 95:14435-14440.
43. Puri A, Hug P, Jernigan K, et al. Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. Biosci Rep 1999; 19:317-325.
44. Hug P, Lin HJ, Korte T, et al. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol 2000; 74:6377-6385.
45. Rawat SS, Gallo SA, Eaton J, et al. Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion. J Virol 2004; 78:7360-7368.
46. Puri A, Rawat SS, Lin H-J, et al. An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS 2004; 18:849-858.
47. Hammache D, Yahi N, Maresca M, et al. Human erythrocyte glycosphingo-lipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J Virol 1999; 73:5244-5248.
48. Nehete PN, Vela EM, Hossain MM, et al. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glyco-sphingolipids is common to entry and infection by diverse HIV-1 strains. Antiviral Res 2002; 56:233-251.
49. Mahfoud R, Garmy N, Maresca M, et al. Identification of a common sphingo-lipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J Biol Chem 2002; 277:11292-11296.
50. Lund N, Branch DR, Mylvaganam M, et al. A novel soluble mimic of the glycolipid globotriaosyl ceramide inhibits HIV infection. AIDS 2006; 20:333-343.
51. Mahfoud R, Mylvaganam M, Lingwood CA, Fantini J. A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction. J Lipid Res 2002; 43:1670-1679.
52. Mylvaganam M, Hansen HC, Binnington B, et al. Interaction of the verotoxin 1B subunit with soluble aminodeoxy analogues of globotriaosyl ceramides. Biochem J 2002; 368:769-776.
53. De Rosa M, Park HJ, Mylvaganum M, et al. The medium is the message: glycosphingolipids and the soluble analogues. Biochim Biophys Acta 2008; 1780:347-352.
54. Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276:1163-1167.
55. Ries M, Clarke JT, Whybra C, et al. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. J Clin Pharmacol 2007; 47:1222-1230.
56. Xu YH, Barnes S, Sun Y, Grabowski GA. Multisystem disorders of glyco-sphingolipid and ganglioside metabolism. J Lipid Res 2010; 51:1643-1675.
57. Lund N, Branch DR, Sakac D, et al. Lack of susceptibility of cells from patients with Fabry disease to productive infection with R5 human immunodeficiency virus. AIDS 2005; 19:1543-1546.
58. Xiao L, Owen SM, Goldman I, et al. CCR5 coreceptor usage of nonsyncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 1998; 240:83-92.
59. Hamanaka R, Shinohara T, Yano S, et al. Rescue of mutant alpha-galacto-sidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. Biochim Biophys Acta 2008; 1782:408-413.
60. Asano N, Ishii S, Kizu H, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxyga-lactonojirimycin and its derivatives. Eur J Biochem 2000; 267:4179-4186.
61. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999; 5:112-115.
62. Ramkumar S, Sakac D, Binnington B, et al. Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. Glycobiology 2009; 19:76-82.
63. Inokuchi J, Radin NS. Preparation of the active isomer of 1-phenyl-2-decan-oylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J Lipid Res 1987; 28:565-571.
64. Abe A, Wild SR, Lee WL, Shayman JA. Agents for the treatment of glyco-sphingolipid storage disorders. Curr Drug Metab 2001; 2:331-338.
65. Harrison AL, Olsson ML, Ramkumar S, et al. Asyntheticglobotriaosylceramide analogue inhibits HIV-1 infection in vitro by two mechanisms. Glycoconj J 2010; 27:515-524.